The impact of COVID-19, including its wide-ranging effect on
"business-as-usual" activities, raises a number of issues
for companies. Listed companies are having to consider their
ongoing disclosure obligations and how to hold shareholder
meetings, and all companies are reviewing the implications of the
coronavirus for their financial position and performance, as well
as their financial arrangements.
Directors need to be mindful of their duties to employees,
shareholders and other stakeholders and, in the context of
transactions, deal timetables are being impacted and termination
rights and logistics reviewed. Companies are also undertaking
supply chain diligence and reviewing contractual terms as part of
the identification of potential areas of legal or regulatory
risk.